Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + encequidar + dostarlimab + carboplatin + trastuzumab
- Development stage
- Unknown
- Lead developer
- Quantum Leap Healthcare Collaborative
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a five-drug combination therapy consisting of oral paclitaxel with encequidar plus dostarlimab, carboplatin, and trastuzumab. Paclitaxel is a taxane-based chemotherapy agent, while encequidar is a P-glycoprotein pump inhibitor that enables oral absorption of paclitaxel. Dostarlimab is a PD-1 inhibitor, carboplatin is a platinum-based chemotherapy, and trastuzumab is an HER2-targeted monoclonal antibody. This specific five-drug combination would likely be used in HER2-positive breast cancer treatment protocols.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)ABCB1 (P-glycoprotein)PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + encequidar + dostarlimab + carboplatin + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + encequidar + dostarlimab + carboplatin + trastuzumab.